Ignite Creation Date:
2025-12-25 @ 5:06 AM
Ignite Modification Date:
2025-12-25 @ 5:06 AM
Study NCT ID:
NCT07242027
Status:
COMPLETED
Last Update Posted:
2025-11-21
First Post:
2025-09-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Use of Lactate-to-Albumin, CRP-to-Albumin, and Procalcitonin-to-Albumin Ratios to Predict Mortality in ICU Patients
Sponsor:
Medical University of Silesia
Organization:
Study Overview
Official Title:
Lactate-to-albumin, CRP-to-albumin and Procalcitonin-to-albumin Ratios Predict Mortality in Critically Ill Adults: a Retrospective ICU Cohort Study
Status:
COMPLETED
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LAR-CAR-PAR
Brief Summary:
This observational study aims to determine whether three blood test ratios - lactate-to-albumin, CRP-to-albumin, and procalcitonin-to-albumin - can predict in-hospital mortality among critically ill adults. The study includes all adult patients admitted in 2024 to the ICU Ward B at the Silesian Center for Heart Diseases (SCCS) in Zabrze. Researchers will analyze retrospective clinical and laboratory data from electronic medical records, including lab values collected at ICU admission, patient demographics, diagnoses, and outcomes. The biomarker ratios will be manually calculated in Excel and statistically evaluated. The main goal is to assess whether these ratios are associated with patient survival and to identify predictive cut-off values to support early risk stratification in the ICU setting.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: